PF 6801591Alternative Names: PF-06801591; PF6801591
Latest Information Update: 09 Mar 2016
At a glance
- Originator Pfizer
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 01 Feb 2016 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT02573259)
- 06 Oct 2015 Pfizer plans a phase I trial for Solid tumours (Second-line therapy or greater ) in USA (NCT02573259)